Navigation Links
Abaxis to Report Third Quarter Fiscal Year 2012 Financial Results Thursday, January 26, 2012
Date:1/17/2012

UNION CITY, Calif., Jan. 17, 2012 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, has scheduled a conference call to discuss its financial results for the third quarter of fiscal year 2012, ended December 31, 2011. The call will be at 4:15 p.m. ET on Thursday, January 26, 2012.  The Company will report financial results for the third quarter of fiscal 2012 after the market closes on Thursday, January 26, 2012.

Participants can dial (877) 317-6789 or (412) 317-6789 to access the conference call, or can listen via a live Internet web cast, which is available in the Investor Relations section of the Company's website at www.abaxis.com. A replay of the call is available by visiting www.abaxis.com for the next 30 days or by calling (877) 344-7529 or (412) 317-0088, confirmation code 10008894, through February 1, 2012.

About Abaxis
Abaxis develops, manufactures, markets and sells portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements.  The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients.  The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples.  The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.  The veterinary business also provides to the animal health and research market a line of hematology instruments for point-of-care complete blood counts (CBC), a specialty instrument to screen for and detect clotting disorders and to measure equine fibrinogen levels, a handheld instrument for the rapid assessment of certain critical care tests and rapid point-of-care tests for Heartworm infections in dogs, Parvovirus and Giardia.  Abaxis, through its AVRL Division, provides routine laboratory testing as well as specialty testing for veterinarians' nationwide.  This state-of-the-art commercial laboratory will be the hub of the Abaxis Veterinary Reference Laboratories (AVRL).Contact:

Clint Severson

Lytham Partners, LLC  

Chief Executive Officer

Joe Dorame, Joe Diaz & Robert Blum  

Abaxis, Inc.

602-889-9700  

510-675-6500

 


'/>"/>
SOURCE Abaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ABAXIS Announces Launch of the First Fully Automated Canine Wellness Profile That Includes a Canine Heartworm Antigen Test
2. Abaxis to Report Second Quarter Fiscal 2010 Financial Results Tuesday, October 27, 2009
3. Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010
4. Abaxis, Inc. to Present at the Sidoti & Company Second Annual New York Institutional Investor Forum
5. Abaxis, Inc. to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Abaxis, Inc. to Present at Sidoti & Companys Ninth Annual West Coast Institutional Investor Forum
7. Abaxis to Report Second Quarter Fiscal 2011 Financial Results Tuesday, October 26, 2010
8. Abaxis Reports Financial Performance with Record Sales for the Second Quarter of Fiscal 2011
9. Abaxis, Inc. to Present at Stephens Fall Investment Conference
10. Abaxis Increases Reagent Disc Offering for Physician Office Market With Release of BioChemistry Panel Plus
11. Abaxis to Report Third Quarter Fiscal 2011 Financial Results Thursday, January 27, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... A key trend that will ... of new treatments. Cardax, a development stage life sciences ... therapy is expected to fulfil large unmet medical needs ... studies to develop new treatments for osteoarthritis. One such ... in osteoarthritis are being investigated, and early trials of ...
(Date:5/25/2016)... FDA 510(k) clearance covers Confocal Miniprobes ... and surgical applications Mauna Kea Technologies ... multidisciplinary confocal laser endomicroscopy (CLE) platform, today announced ... the 12 th 510(k) clearance from United ... FDA clearance covers Confocal Miniprobes indicated for use ...
(Date:5/25/2016)...  Zymo Research Corp. announced today the final ... that help researchers obtain the most accurate and ... rapid growth of the study of microbiomes has ... methods to improve the reproducibility and quality of ... every step of the measurement process including collection ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of ... Tribute to Women and Industry (TWIN) 2016 honorees. The award recognizes businesswomen who ... this year, Geri Boone, Director of the MLTSS (Managed Long-Term Services and Supports) Program ...
(Date:5/27/2016)... ... 27, 2016 , ... This campaign aims to provide a path to improved ... can control and change. , As nearly 795,000 Americans suffering from a new or ... States. Plus, with an estimated 129,000 of these people dying from stroke, it’s become ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses ... human interest stories, courtesy of leaders in the nursing and health care industry. ... from leading advocates and associations—namely Jones & Bartlett Learning. , Jones & Bartlett ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... Despite last ... meeting, expect Janet Yellen and company to wait until March 2017 for an interest ... University’s J. Mack Robinson College of Business. , “The Federal Open Market Committee (FOMC) ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... hosted members and suppliers for its inaugural Member Conference at the Paris Hotel ... of elevating the operational health of America’s healthcare providers. , The conference was ...
Breaking Medicine News(10 mins):